Please use this identifier to cite or link to this item:
https://hdl.handle.net/11499/7890| Title: | Intravitreal bevacizumab therapy in non-arteritic anterior ischemic optic neuropathy | Authors: | Çetin, E.N. Akduman, L. |
Keywords: | Anti-vascular endothelial growth factor Bevacizumab Non-arteritic ischemic optic neuropathy bevacizumab adult afferent pupillary defect aged anterior ischemic optic neuropathy article case report human ischemic optic neuropathy male papilledema treatment outcome visual acuity visual field visual field defect visual impairment |
Abstract: | Up to date there is no golden standard for the treatment of non-arteritic ischemic optic neuropathy. Here we report two cases which underwent intravitreal bevacizumab injection for non-arteritic ischemic optic neuropathy. In the first case, visual acuity changed from 2/200 to 20/400 at 2 week and 4/200 at one year. In the second case, visual acuity decreased from 20/30 to 20/400 with a worsened visual field defect at 6 week and to 20/200 at 5.5 month. Bevacizumab did not seem to improve visual outcome in non-arteritic ischemic optic neuropathy. | URI: | https://hdl.handle.net/11499/7890 | ISSN: | 1300-1256 |
| Appears in Collections: | Scopus İndeksli Yayınlar Koleksiyonu / Scopus Indexed Publications Collection Tıp Fakültesi Koleksiyonu |
Show full item record
CORE Recommender
SCOPUSTM
Citations
2
checked on Jun 29, 2024
Page view(s)
16
checked on May 27, 2024
Google ScholarTM
Check
Items in GCRIS Repository are protected by copyright, with all rights reserved, unless otherwise indicated.